Life Sciences Archive » March, 2026

Life Sciences - March, 2026

293 articles

• Split 4th Circ. Affirms Injunction On W.Va. Drug Discount Law
• Novartis Seeks To Block New Wash. 340B Drug-Pricing Law
• Novartis Can't Nix FCA Suit Alleging MS Drug Kickbacks
• Anesthesia Parent Can't Duck Antitrust Suit, But Affiliate Can
• Moderna, Pfizer Want Bayer's COVID-Shot Patent Suits Tossed
• BioPharma Spoofing Suit Against Canadian Banks Proceeds
• Full Fed. Circ. Is Told Panel Defied EcoFactor In DePuy Case
• Biogen Paying $5.6B For Apellis As 4 Firms Advise
• Beasley Allen Seeks Stay Of DQ In Federal J&J Talc MDL
• Insurer Says Yale Was 'Misleading' In $4.1M Transplant Claim
• Kirkland, Goodwin Steer Lilly $7.8B 'Sleep-Wake' Disorder Deal
• Cancer Vaccine Developer Files Ch. 7 After Trials Fall Short
• Getting The Most Out Of Learning And Development Programs
• Don't Set Special IP Rules For 'Skinny Labels,' Justices Told
• FCA Qui Tams Are Unconstitutional, Eli Lilly Tells Justices
• Sanofi Claims IP Life Extension Needed For Double Patenting
• Cleary-Led Blackstone Wraps Record $6.3B Life Sci Fund
• Eli Lilly's $2.75B Pact Is Latest In AI Drug Discovery Push
• Del. Judge Upholds $34M Verdict In Glaucoma Patent Feud
• J&J Unit Wants Forensic Exam Of Ex-Director's Devices
• Eagle Pharma To Pay $9.5M To End Channel Stuffing Claims
• AI Presents A Make-Or-Break Moment For Outside Counsel
• High Court Turns Away CRISPR Patent Validity Dispute
• Justices Pass On FCA Suit Alleging Quest Diagnostics Fraud
• Justices Reject TM Appeal Tied To 'Use In Commerce'
• Elizabeth Holmes Gets 11-Year Prison Sentence Cut By A Year
• Eli Lilly Keeps Most Of Weight Loss Drug Copy Suit Alive
• Del. Justices Won't Revive Hedge Fund Insider Trading Case
• Hospital System Beats Most Of REIT's $50M Floodwall Suit
• Nobel Prize Winners Again Lose Patent Fight Over CRISPR
• Skincare Co. Says ITC Ruling Backs Ending PTAB Challenge
• USPTO Has A Chance To Correct Double-Patenting Doctrine
• Sens. Push Bill To Equip VA For Psychedelic Therapies
• Biopharma's Brass Hid Anxiety Drug Trial Risks, Investor Says
• Biogen Beats Investor Suit Over Dozens Of Drug Claims
• Mississippi Gov. Vetoes Medical Marijuana Expansion Bill
• NJ Federal Judge DQs Beasley Allen In J&J Talc MDL
• Pharma Co. Says Exec Was Fired Over Conduct, Not Piglets
• Navigating Life Sciences Deals Amid Heightened Scrutiny
• Kirkland-Led Transcend Bought By Otsuka In $1.2B Deal
• Watching Hallmark Movies Makes Me A Better Lawyer
• Elanco Beats Investor Suit Over Dog Drug's Reg Challenges
• Fed. Circ. Rejects Pharma Co. Refiling Suit To Reset Deadline
• Legislative Update: Cannabis And Psychedelics Bill Roundup
• McDonald Hopkins Must Produce Fraud Warning Docs
• Abbott Unit Beats Ex-Worker's Whistleblower Suit At 8th Circ.
• Pa. Justices Deem Pot Group Unharmed By Abstinence Rule
• 9th Circ. Upholds Medtronic Win In Spinal Cord Device Suit
• Regeneron Can't Sink Disability Bias Claims Over Scheduling
• PTAB Was Never '100% Discretionary,' Rep. Issa Tells Squires
• AbbVie, Novartis Sue Wash. Over New 340B Drug-Pricing Law
• Ex-Pharma GC Freed From Trade Secrets Suit Amid Ch. 7 Stay
• Co.'s Dual Citizenship Doesn't Kill Jurisdiction, 4th Circ. Told
• New Orphan Drug Law Provides A Key Fix For Pharma Cos.
• Mom Tying Abbott Formula To Baby's NEC Takes The Stand
• Fecal Treatment Co. Says Ch. 11 Is Best Option To Sell Assets
• Judge Trims SEC Fraud Case Over Cancer Drug Claims
• Insurer Need Not Cover Parkinson's Drug Antitrust Dispute
• Biotech 'Lowballed' Landlord On Lease Exit, Suit Says
• Dechert Adds Paul Weiss Patent Partners In DC, NY
• When Trade Secret Litigation And Criminal Law Collide
• Covington, Freshfields Advise On $6.7B Merck Oncology Deal
• Trump Admin Settles Suit Over Biden Social Media Collabs
• Nicotine Pouch Maker To Refile FDA Suit In DC After Transfer
• Agenus Escapes Investor Fraud Suit Over Cancer Drug
• Drug Co. Atara Hit With Investor Suit Over FDA Denial
• Squires Institutes 6 Patent Reviews, Denies 15 Others
• Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP
• ITC Says Hydrafacial Patent Infringed, But Won't Ban Imports
• PTAB Needs Reform To Protect Inventors From Larger Cos.
• CBP Frees Redesigned Smart Rings From Import Ban
• Fla. Judge Tosses Fired Reporter's Vaccine Suit Against PGA
• FTC Rejects Bids To Block Gender-Affirming Care Probe
• FDA User Fee Talks Offer Clues On Upcoming Reforms
• 6 Firms Guide Gilead's $2.2B Autoimmune Drug Play
• Alston & Bird Hires Ex-FDA Deputy Counsel From DLA Piper
• FTC To Mull Caremark Deal In PBM Insulin Pricing Case
• Beasley Allen Says NJ Justices Review Of Talc DQ 'Essential'
• Ohio Justices Likely Split On Trans Care Restrictions
• Fired Ipsen Director Accuses The Pharmaceutical Co. Of Bias
• Justices Won't Review Class Cert. In Diabetes Drug Risk Case
• CooperSurgical Fights Docs Request In Embryo Loss Suit
• Amarin Tells Justices Hikma Drug Patent Appeal Threatens IP
• Revance Investors Ink $17M Deal In Take-Private Offer Suit
• J&J Amici Seek Clarity On Goldman Precedent For Class Cert.
• Stem Cell Clinic Accused Of Deceiving Patients
• Med Mal Claims Proceed In Fertility Clinic Wrong Sex Suit
• Novartis Faces Class Suit Over Patient Health Info Disclosure
• Agilent, Axion End Cell Analysis IP Suit After Jury Selection
• Moderna Case Highlights Overlooked Hurdle In Biopharma IP
• Federal Prosecutors Fight Bail Bid For Convicted Biotech CEO
• Feds Approve Minnesota's Plan To Combat Medicaid Fraud
• AbbVie Escapes Ill. Genetic Privacy Lawsuit
• High Court Won't Hear Mich. Newborn Blood Testing Case
• Fecal Treatment Co. Files Ch. 11 To Escape Lease, Sell IP
• Catching Up With Delaware's Chancery Court
• Justices Won't Review Lab Owner's Kickback Conviction
• Justices Pass On Challenge To Courts' Sanctions Authority
• Feds Rip Ex-NFL Player's New Trial Bid Over Medicare Scheme
• Former Gilead Sciences GC To Earn Over $2.5M Severance
• CytoDyn Settles Investor Suit With $500K, 49M Shares
• Feds To Cover Ayahuasca Church's Legal Fees, 9th Circ. Says
• EPA's Ethylene Oxide Plan May Hinder Other Air Toxics Regs
• Eli Lilly Beats 9th Circ. Appeal Over Brain Bleed After Cialis
• IVF Patients Say Co. Misled Them On Genetic Test's Accuracy
• FDA Framework For Personalized Therapies Raises Questions
• Fed. Circ. Backs Military In Veterinary Software Dispute
• Emissions Permits May Not Override Pollution Exclusions
• Hims Says Failed Wegovy Collab Doesn't Merit Investor Suit
• 5 Tips For Navigating Your Firm's All-Attorney Summit
• Beasley Allen Can't Halt DQ Ruling In J&J Talc Litigation
• Hong Kong Backer Accuses Med Co. Founders Of Self-Dealing
• Prestige Picks Up Breathe Right In $1.05B Deal
• 4th Circ. Leery Of W.Va. Opioid Towns' Abatement Arguments
• Chan Zuckerberg Initiative Hit With Gender Bias Action
• Pharma Group Can't Halt Colo. Law Over Drug Discount Rules
• Apple Watch Redesign Gets Early OK As Patent Loss Upheld
• Legislative Update: Cannabis And Psychedelics Bill Roundup
• Drug Co. Can't Claim Most Docs Contain Trade Secrets At Trial
• Still No Shenanigans: Fed. Circ. Keeps Review Bar High
• Calif. Families Sue Rady Health Over Move To End Trans Care
• Goodwin, S&C Steer Up To $785M Sale Of ADHD Drug
• CVS, Caremark Pocket Money Meant For Rebates, Suit Claims
• Zynex Gets OK For Ch. 11 Plan Reducing Debt By $50M
• Coaching Soccer Makes Me A Better Lawyer
• Key Details As 3rd Circ. Ponders FCA's Fate, $1.6B J&J Fine
• Apple Took Masimo IP But No Remedy Warranted, Judge Says
• Stryker Hit With Another Suit After Cyberattack
• FINRA Says Compliance Chief Took Part In Pre-IPO Fraud
• Squires' Latest Order Grants 9 Patent Reviews, Spurns 6
• Abbott Investors Ink $40M Deal Over Infant Formula Crisis
• USPTO Wants 900 New Patent Examiners By October
• NC Judge Moves Ex-Exec's Wage Fight With Cancer Co. To Va.
• Food Cos. Get Another Shot At David Protein Antitrust Case
• DLA Piper Lands Shook Hardy Products Liability Pro In Miami
• Axion Cleared Of False Advertising Before Agilent Patent Trial
• Law School's Missed Lessons: The Human Element
• Biotech Investor Blames Pierce Atwood For Messy Asset Sale
• Latham Hires Desmarais IP Partner In DC
• Pot Co. Escapes Potency Suit, Judge Warns Plaintiff Firm
• NeoGenomics Beats Investor Suit Over Growth Driver Claims
• 9th Circ. Backs Rare FCA Theory In Huge Drug Prices Program
• Bard And AngioDynamics Resolve 11-Year Patent Dispute
• Dr. Oz Claims Florida Also Has Healthcare Fraud Problem
• Geico Keeps RICO, Fraud Claims In NY No-Fault Billing Suit
• Avoid The Unexpected When Drafting License Agreements
• Bipartisan Bill To Waive $100K H-1B Fee Gets AMA Backing
• Edwards Beats Heart Valve IP Suit Just Before Trial
• Cipla To Hold Off On Pediatric Cancer Drug Generic Until 2033
• Alcon Drops $430M Lensar Deal Under Pressure From FTC
• WTO Must Extend Digital Trade Protections, Lawmakers Told
• Drug Developer GNQ To Go Public Via $500M SPAC Deal
• CMS Healthcare Enforcement Initiatives May Cause Disruption
• McGuireWoods Adds Former CDC Scientist From McDermott
• Fenwick Healthcare Regulatory Atty Rejoins Latham In LA
• 1st Circ. Affirms Block Of Trump's 'Unprecedented' Aid Freeze
• Judge Tosses Kaiser Whistleblowers' Claims After $556M Deal
• Lannett Investors Seek Final OK Of $5.8M Price-Fix Probe Suit
• J&J's Lack Of Malice Gets $966M Talc Verdict Cut To $16M
• Medtronic Seeks To Ax 'Extreme Outlier' $382M Antitrust Loss
• Amgen And Sanofi End Repatha IP Fight Heard By Justices
• Italy's Amplifon Buying Danish Hearing Device Biz For $2.6B
• HHS' Childhood Vaccine Policy Changes Put On Ice
• The Benefits Of Choosing A Niche Practice In The AI Age
• Catching Up With Delaware's Chancery Court
• AIG Policy Excludes $150M Pollution Coverage, 7th Circ. Finds
• Maryland Bros. Get Prison For HIV Drug Fraud Scheme
• She Has A Point: Finnegan's Cora Holt
• Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit
• 4th Circ. Brings Back Allergan Medicaid Overcharging Suit
• How PBMs Can Adapt To Plan Sponsors' Disclosure Demands
• Sandoz Appealing Ruling Over Amgen's Enbrel Biosimilar
• What New Animal Welfare Enforcement Push Means For Cos.
• Kroger Agrees To Pay $17M In Drug Copay Inflation Case
• Life Sciences Partner Hiring Up Amid Regulatory Scrutiny
• J&J Unit Says Ex-Director Misappropriated Trade Secrets
• Orthopedics Co. Investors See Merger Claims Trimmed
• DC Circ. Spends Hours Debating 'Same' Generic Label Reqs
• Tom's Toothpaste Trims Class Action Over Lead Levels
• IP Notebook: TM Use Fight, Popeye, Kurt Cobain
• Embryo Loss Suits Need 'Serious' Edits, Judge Told
• US Chamber Report Warns Of Risks To IP Protection
• How To Engage With Gov't's Direct-To-Consumer Drug Policy
• Epilepsy Drugmaker's Statements Insulated From Stock Suit
• Del. Chancery Rejects Fraud Claims In $313.5M Fertilizer Deal
• Podcasting Makes Me A Better Lawyer
• DNA Testing Co. Can't Shake Suit Over Genetic Data Sharing
• Eli Lilly Ordered To Arbitrate Alzheimer's Drug Feud
• New Wyoming Abortion Law Faces Familiar Legal Challenge
• La. Fights Dismissal Bid In Abortion Regulation Dispute
• Insulin Makers Ask Justices To Review Collusion Case
• Pharma Co. Says Ex-Director Using Trade Secrets At New Job
• Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts
• Bayer Sees 'Light At The End Of The Tunnel' In Roundup Suits
• Pa. Justices Doubtful Law Unclear In AG-DA Opioid Deal Row
• Anthem Beats Lab's $1.9M ERISA Payment Demand
• Minn. Lawmakers Advance Medical Psilocybin Bill
• Tax Court Ruling Signals Cross-Border Loan Scrutiny
• MoFo Private Equity Atty Joins Greenberg Traurig In Miami
• Biomedical Co. Settles Trade Secrets Case Against Ex-Worker
• Investor Urges Revival Of Armistice Insider Trading Claims
• Justices Advised To Keep Law Clear In 'Skinny Label' Case
• J&J Unit Wins Sanction In Talc Libel Case
• 5th Circ. Revives J&J Sales Rep's Wage Dispute
• Sanofi Says Judge Botched Insulin Device Patent Listings
• Lab's Aetna Payment Suit Survives, But With Deep Cuts
• FDA To Consider Coffee, 'Spice' E-Cig Flavors
• CVS Can't 'Relitigate' Price-Gouging Class Cert.
• Lessons From Justices' Split On Major Questions Doctrine
• Former Conn. Prosecutor Can Stay On Generic-Drug Case
• Medtronic Expands Vascular Device Line With $550M Deal
• J&J Opposes Beasley Allen Reinstatement Bid In NJ Talc Fight
• Drug Wholesaler's DPA Shows Imperfect Efforts Still Count
• Texas AG Gets Temporary Ban On Chest Binder Sales
• Abortion Rights Group, SD Agree to End Gas Station Ads Row
• Novo, Hims & Hers Make Up, Agree To Sell GLP-1s Together
• Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says
• Astellas Prevails In Patent Battle Over Bladder Drug
• Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot
• McGuireWoods Beats Sun Pharma's DQ Bid In NJ Suit
• When MDLs Drag, State Courts Can Speed Mass Tort Results
• Sullivan & Cromwell Advises Agilent On $950M Biocare Buy
• JPMorgan Trims But Can't Escape ERISA Drug Costs Suit
• Atty Should've Checked Docket, Says Philips CPAP Judge
• ExThera Exec Hid Patient Deaths To Keep $10M Deal, DOJ Says
• FDA Vaccine Chief Prasad To Exit Agency For 2nd Time
• Drugmaker Nektar Faces Suit Over Hair Loss Drug Trial Claims
• Actelion Pays $65M To Settle Tracleer Antitrust Class Suit
• 9th Circ. Mulls Whether Politics Tainted DOJ Trans Care Probe
• Boston Scientific Investor Sues Over Growth Projections
• Mass. Judge Told Vax Committee Must Be Fairly Balanced
• Fed. Circ. Won't Reinstate $2M Sepsis-Testing Patent Verdict
• NJ Talc Suit Will Proceed Amid Beasley Allen DQ Appeal
• Sanofi Selling Medley Unit To Brazilian Drug Co. For $500M
• Express Scripts Ducks RICO Suit Over Acthar Price Hike
• Pa. High Court Snapshot: AG Powers, Gun Parts, CEO Bonus
• Baker McKenzie Guides Servier On $2.5B Oncology Deal
• Leveraging MDLs And State Courts In Mass Tort Strategy
• Telehealth Co. Swaps In Gordon Rees In Novo's GLP-1 Fight
• Fintech Sues Deutsche Bank, Pathward Over Pharma Flags
• Top Patent Officials To Review Sanofi's Double Patenting Win
• Pharma Co. Investors Secure Class Cert. Over FDA Obstacles
• Drugmaker Aquestive Hit With Suit Over FDA Approval Delay
• Pfizer Gets OK For $29M SEC Payout From Insider Case
• Progenity Investors' $1M Billing Fraud Suit Deal Gets Final OK
• Fed. Circ. Mulls Patents In Penile Implant Trade Secret Win
• 9th Circ. Judge 'Frustrated' At DOJ Position On Anti-Trans EOs
• Squires' Newest Quick Order Grants 5 Petitions, Rejects 4
• Unique Issues Facing Brand-Compounder Patent Litigation
• Fla. Lab Pays $980K To Settle Kickback Allegations
• Insurer Seeks Win In $6.3M Coverage Row With Pot Tester
• Volunteering With Scouts Makes Me A Better Lawyer
• Wheeling & Appealing: The Latest Must-Know Appellate Action
• CVS Beats Antitrust Suit Over 340B Drug Program, For Good
• Del. Judge Mocks IP Owner, But Still: 'Defendants Win? No!'
• Regeneron, Sanofi Didn't Warn About Cancer Risk, Suit Says
• Zantac Investor Class Action Time-Barred, Pa. Judge Rules
• GAO Denies Protest Of $39.5M Defense Logistics Contract
• 9th Circ. Hesitant To Revive Implant Suit Against Medtronic
• DC Judge Strikes Down 340B Drug Discount Registration Rule
• Law School's Missed Lessons: In Court, It's About Storytelling
• Pros And Cons Of FDA's Push For Nonprescription Drugs
• Sandoz Parent Targets Walmart, Southwest Generic Drug Suits
• Buyers Finalize $58M Generic-Pricing Deal With 3 Drugmakers
• Judge Sets 'Hard Deadline' To Rule On Childhood Vax Policy
• Moderna To Pay At Least $950M To End COVID-19 Vax IP Fight
• EPA Fights Fluoridated Water IQ Risk Finding At 9th Circ.
• Calif. Sued Over Cancer Warning Law For Personal Care
• BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit
• Death From Stem Cell Treatment For ALS Draws $24M Verdict
• Ex-FDA Leaders Rebut Contraception Rollbacks At 3rd Circ.
• FDA Targets Advertising For Knockoff Weight-Loss Meds
• How Recent Del. Rulings Clarify M&A Deal Fraud Carveouts
• Sanofi Gets Approval For Interlocutory Appeal In Taxotere MDL
• High Court's 'Skinny Label' Case May Tackle Wider Questions
• Fed. Circ. Revives Challenge To Augmented Reality Surgical IP
• Aligning Microsoft Tools With NYC Bar AI Recording Guidance
• States Can't Duck Regeneron Counterclaims In FCA Case
• Genentech Says Biocon Importing Infringing Cancer Drugs
• 1st Circ. Won't Revive Boston's Opioid Claims Against PBMs
• FTC Makes 'Significant Progress' In OptumRx, Caremark Talks
• Abbott Beats Data Sharing Suit Over Glucose Tracking Trial
• AI Drugmaker BioXcel Eyes $9.8M Investor Settlement
• Epic Must Face Price Conspiracy Claims Over Gallstone Drug
• Chancery Orders Receiver As EpicentRx Fails To Pay $425K
• Amazon Can't Halt Supplement Labeling Suit Amid FDA Tweak
• FDA's Biosimilarity Guidance Holds Uncertain Implications
• Unpacking Key Themes From NY's New Healthcare Strategy
• 5 Different AI Systems Raise Distinct Privilege Issues
• Hagens Berman Denied Rehearing Bid In Sanctions Dispute
• Gyre, Cullgen Merge In $300M All-Stock Deal
• J&J Unit Wins Bid To Revive Talc Libel Suit With New Basis
• Drugmakers Warn Justices Oregon Pricing Law Risks Secrets